A Retrospective Study to Describe Real-World Treatment Patterns and Clinical Outcomes Among Patients With Myelodysplastic Syndromes
← catalyst calendarSponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
—
Status
Withdrawn
Study type
Observational
Enrollment
0actual
Sites
1
Country
Taiwan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Sponsor decision
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-11-30 | estimated | When the study began enrolling |
| Primary completion | 2025-03-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-03-30 | estimated | The whole study's end, after follow-up |
| First posted | 2024-08-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-10-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Myelodysplastic Syndromes (MDS)
Interventions
- Drug: Luspatercept
- Drug: Epoetin Alfa
Primary outcomes
what the primary-completion date above is the date OFParticipant treatment patterns: Type of treatment received
measured Up to 24 months
Participant treatment patterns: Duration of treatment received
measured Up to 24 months
Participant treatment patterns: Dosage of treatment received
measured Up to 24 months
Participant treatment patterns: Dosing route of treatment administration
measured Up to 24 months
Participant treatment patterns: Reason for treatment administration
measured Up to 24 months
Participant treatment patterns: Time to next line of therapy (LoT)
measured Up to 24 months
Participant treatment patterns: Reason for treatment discontinuation
measured Up to 24 months
Participant treatment patterns: Type of concomitant medications received
measured Up to 24 months
Participant treatment patterns: Start and end dates of concomitant medications received
measured Up to 24 months
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed